200 related articles for article (PubMed ID: 26972640)
1. Association Between Treatment at a High-Volume Facility and Improved Survival for Radiation-Treated Men With High-Risk Prostate Cancer.
Chen YW; Mahal BA; Muralidhar V; Nezolosky M; Beard CJ; Den RB; Feng FY; Hoffman KE; Martin NE; Orio PF; Nguyen PL
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(4):683-90. PubMed ID: 26972640
[TBL] [Abstract][Full Text] [Related]
2. The association between facility case volume and overall survival in patients with metastatic renal cell carcinoma in the targeted therapy era.
Chen YW; Ornstein MC; Wood LS; Allman KD; Martin A; Beach J; Gilligan T; Garcia JA; Rini BI
Urol Oncol; 2018 Oct; 36(10):470.e19-470.e29. PubMed ID: 30131292
[TBL] [Abstract][Full Text] [Related]
3. Effect of Radiation Treatment at a High-Volume Center on Outcomes in Intermediate-Risk Prostate Cancer: An Analysis of the National Cancer Database.
Lim M; Qureshi MM; Boyd G; Hirsch AE
Urology; 2022 Jul; 165():242-249. PubMed ID: 35182584
[TBL] [Abstract][Full Text] [Related]
4. Analysis of Radiation Facility Volume and Survival in Men With Lymph Node-Positive Prostate Cancer Treated With Radiation and Androgen Deprivation Therapy.
Patel SA; Goyal S; Liu Y; Moghanaki D; Patel PR; Hanasoge S; Dhere VR; Shelton JW; Godette KD; Jani AB; Hershatter B; Fischer-Valuck BW
JAMA Netw Open; 2020 Dec; 3(12):e2025143. PubMed ID: 33301015
[TBL] [Abstract][Full Text] [Related]
5. The Impact of Academic Facility Type and Case Volume on Survival in Patients Undergoing Curative Radiation Therapy for Muscle-Invasive Bladder Cancer.
Bajaj A; Martin B; Bhasin R; Hentz C; Block AM; Harkenrider MM; Solanki AA
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):851-857. PubMed ID: 29485062
[TBL] [Abstract][Full Text] [Related]
6. Survival Outcomes of Whole-Pelvic Versus Prostate-Only Radiation Therapy for High-Risk Prostate Cancer Patients With Use of the National Cancer Data Base.
Amini A; Jones BL; Yeh N; Rusthoven CG; Armstrong H; Kavanagh BD
Int J Radiat Oncol Biol Phys; 2015 Dec; 93(5):1052-63. PubMed ID: 26581142
[TBL] [Abstract][Full Text] [Related]
7. Influence of treatment center and hospital volume on survival for locally advanced cervical cancer.
Wright JD; Huang Y; Ananth CV; Tergas AI; Duffy C; Deutsch I; Burke WM; Hou JY; Neugut AI; Hershman DL
Gynecol Oncol; 2015 Dec; 139(3):506-12. PubMed ID: 26177552
[TBL] [Abstract][Full Text] [Related]
8. Radiation Facility Volume and Survival for Men With Very High-Risk Prostate Cancer Treated with Radiation and Androgen Deprivation Therapy.
Sebastian N; Goyal S; Liu Y; Janopaul-Naylor JR; Patel PR; Dhere VR; Hanasoge S; Shelton JW; Godette KD; Jani AB; Hershatter B; Fischer-Valuck B; Patel SA
JAMA Netw Open; 2023 Aug; 6(8):e2327637. PubMed ID: 37552479
[TBL] [Abstract][Full Text] [Related]
9. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
Fizazi K; Faivre L; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houede N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Chinet-Charrot P; Legouffe E; Lagrange JL; Linassier C; Deplanque G; Beuzeboc P; Davin JL; Martin AL; Habibian M; Laplanche A; Culine S
Lancet Oncol; 2015 Jul; 16(7):787-94. PubMed ID: 26028518
[TBL] [Abstract][Full Text] [Related]
10. Retrospective evaluation reveals that long-term androgen deprivation therapy improves cause-specific and overall survival in the setting of dose-escalated radiation for high-risk prostate cancer.
Feng FY; Blas K; Olson K; Stenmark M; Sandler H; Hamstra DA
Int J Radiat Oncol Biol Phys; 2013 May; 86(1):64-71. PubMed ID: 23462420
[TBL] [Abstract][Full Text] [Related]
11. Brachytherapy improves biochemical failure-free survival in low- and intermediate-risk prostate cancer compared with conventionally fractionated external beam radiation therapy: a propensity score matched analysis.
Smith GD; Pickles T; Crook J; Martin AG; Vigneault E; Cury FL; Morris J; Catton C; Lukka H; Warner A; Yang Y; Rodrigues G
Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):505-16. PubMed ID: 25596107
[TBL] [Abstract][Full Text] [Related]
12. Facility Volume and Survival in Nasopharyngeal Carcinoma.
Yoshida EJ; Luu M; David JM; Kim S; Mita A; Scher K; Shiao SL; Tighiouart M; Lee NY; Ho AS; Zumsteg ZS
Int J Radiat Oncol Biol Phys; 2018 Feb; 100(2):408-417. PubMed ID: 29100787
[TBL] [Abstract][Full Text] [Related]
13. Association Between Treatment at High-Volume Facilities and Improved Overall Survival in Soft Tissue Sarcomas.
Venigalla S; Nead KT; Sebro R; Guttmann DM; Sharma S; Simone CB; Levin WP; Wilson RJ; Weber KL; Shabason JE
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):1004-1015. PubMed ID: 29485042
[TBL] [Abstract][Full Text] [Related]
14. Differential post-prostatectomy cancer-specific survival of occult T3 vs. clinical T3 prostate cancer: Implications for managing patients upstaged on prostate magnetic resonance imaging.
Muralidhar V; Dinh KT; Mahal BA; Ziehr DR; Chen YW; Viswanathan VB; Nezolosky MD; Choueiri TK; Hoffman KE; Hu JC; Sweeney CJ; Trinh QD; Nguyen PL
Urol Oncol; 2015 Jul; 33(7):330.e19-25. PubMed ID: 25990612
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
Lee AK; Levy LB; Cheung R; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
[TBL] [Abstract][Full Text] [Related]
16. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
Demanes DJ; Brandt D; Schour L; Hill DR
Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
[TBL] [Abstract][Full Text] [Related]
17. Impact of treating facilities' type and volume in patients with major salivary gland cancer.
Bollig CA; Zitsch RP
Laryngoscope; 2019 Oct; 129(10):2321-2327. PubMed ID: 30698823
[TBL] [Abstract][Full Text] [Related]
18. Percentage of positive biopsy cores: a better risk stratification model for prostate cancer?
Huang J; Vicini FA; Williams SG; Ye H; McGrath S; Ghilezan M; Krauss D; Martinez AA; Kestin LL
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1141-8. PubMed ID: 22099043
[TBL] [Abstract][Full Text] [Related]
19. Short-term androgen-deprivation therapy improves prostate cancer-specific mortality in intermediate-risk prostate cancer patients undergoing dose-escalated external beam radiation therapy.
Zumsteg ZS; Spratt DE; Pei X; Yamada Y; Kalikstein A; Kuk D; Zhang Z; Zelefsky MJ
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(4):1012-7. PubMed ID: 22981709
[TBL] [Abstract][Full Text] [Related]
20. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.
Zapatero A; Guerrero A; Maldonado X; Alvarez A; Gonzalez San Segundo C; Cabeza Rodríguez MA; Macias V; Pedro Olive A; Casas F; Boladeras A; de Vidales CM; Vazquez de la Torre ML; Villà S; Perez de la Haza A; Calvo FA
Lancet Oncol; 2015 Mar; 16(3):320-7. PubMed ID: 25702876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
